"We believe Dr. Leaman’s insights and guidance will be invaluable as we prepare to enroll subjects in Phase 2 studies ...

A team of researchers have discovered a powerful bispecific inhibitor capable of combating all existing human-pathogenic ...

Enanta intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and short-term and long-term investments, to fund its clinical trials, research, and ...

NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that it has received a Notice of Allowance from the U.S. Patent ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced ...

A new broad-spectrum coronavirus antiviral, ASAP-0017445, has been nominated as a pre-clinical drug candidate by the Drugs ...

KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, ...

In preclinical studies—including in vitro, ex vivo, and in vivo models—RVB-003 demonstrated robust efficacy with a remarkable ...

Researchers evaluated the prevalence of low-level viremia and its influence on the risk for virologic failure in patients with HIV on antiretroviral therapy.

COCP READ THE FULL COCP RESEARCH REPORT Business Update CDI-988 Overview Presented at Calicivirus Conference On September 12, 2025, Cocrystal Pharma Inc. (NASDAQ:COCP) announced that its Presidents ...

This study presents a valuable finding that KDM5 inhibitors may enable a wide therapeutic window as compared to STING agonists or Type I Interferons. The evidence supporting the claims of the authors ...

Matt Nadel’s documentary short explores the moral complexities of buying the life-insurance policies of H.I.V.-positive gay ...